|
Jan 29
|
Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial
|
|
Jan 14
|
Majority of Individuals with Atopic Dermatitis Improved with Arcutis’ Roflumilast Cream 0.15% According to New Data from Phase 3 Program
|
|
Jan 14
|
ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids
|
|
Jan 12
|
Best Momentum Stocks to Buy for January 11th (Revised)
|
|
Jan 12
|
Are Medical Stocks Lagging Amarin (AMRN) This Year?
|
|
Dec 28
|
The Zacks Analyst Blog Highlights Allogene Therapeutics, Arcutis Biotherapeutics and C4 Therapeutics
|
|
Dec 27
|
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
|
|
Dec 24
|
11 High Growth Micro-Cap Stocks to Buy
|
|
Dec 19
|
Arcutis (ARQT) Up on FDA Nod for Zoryve in Seborrheic Dermatitis
|
|
Dec 18
|
Arcutis shares jump after FDA approves drug for chronic skin condition
|
|
Nov 29
|
FDA Accepts Arcutis’ Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6
|
|
Nov 17
|
After Plunging -35.64% in 4 Weeks, Here's Why the Trend Might Reverse for Arcutis Biotherapeutics, Inc. (ARQT)
|
|
Nov 17
|
Polar Capital Holdings Plc Bolsters Portfolio with Arcutis Biotherapeutics Inc Stake
|
|
Nov 5
|
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2023 Earnings Call Transcript
|
|
Nov 3
|
Arcutis Biotherapeutics Inc (ARQT) Reports Q3 2023 Earnings: Revenue Soars to $38.1 Million
|
|
Nov 3
|
Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update
|
|
Nov 2
|
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Sep 27
|
Arcutis Appoints L. Todd Edwards as Chief Commercial Officer
|
|
Sep 27
|
Roivant Sciences Ltd. (ROIV) Moves 21.6% Higher: Will This Strength Last?
|
|
Sep 25
|
Mizuho reaffirms 'Buy' recommendation for Arcutis Biotherapeutics, amidst mixed institutional sentiment
|